CGT Industry Upgrade Series - Chengdu Tianfu International Biomed City Stop Announced with Lineup and Product Highlights

Jul 08, 2024 14:05 CST Updated 14:05

Event Information

■ Stop 9: Chengdu Tianfu International Bio-Town

Event Name:【No Need to Compete Fiercely, Go Further】 CGT Industry Upgrade Series · Park Tour — Ninth Stop: Chengdu Tianfu International Bio-town

Organizer:Healthcare Innovative Ecosystem Alliance (HIEA)

Co-organized by:Xingcheng Biotech, Yeasen Biotechnology, Lepu Biopharma, VectorBuilder, Danaher Life Sciences, Levostar Biotech, Legend Capital

XieOrganizer：Chengdu Guosheng Innovation Technology Service Co., Ltd.

Organizer:Artery New Medicine

Event Duration:July 16, 2024 (Tuesday) 13:30

Event Location:2F, Multi-Function Hall, Hyatt Place Chengdu Bio-Town, No. 1 Huigu Road, Shuangliu District, Chengdu

Method of Participation:Scan the QR code in the article to register for free

Chengdu Tianfu International Bio-City – Actual View

Event Scale: 50 people/session

Free AdmissionRegistration:

Capillaries 17782369627 (WeChat ID same)

Event Collaboration:

Ms. Fu 17851017836 (WeChat ID same)

👇Long-press to scan the QR code and add as a friend to register👇

# Highlights

CGT from an Investment Perspective:Leveraging the strategic insights of investors and corporate business development leaders, this analysis distills new pathways for innovative pharmaceutical companies to secure funding, empowering them to navigate growth opportunities and challenges.

Optimal Supply Chain Solutions During Extraordinary Times:By listening to Party A’s needs, supply chain companies collaborate to explore the most suitable solutions, striving to help innovative enterprises transition smoothly, rapidly, and cost-effectively from preclinical stages to IND filing and other key milestones.

Global Insights · CGT Quality Management:Focus on the Frontier: An In-Depth Exploration of End-to-End Quality Control in Cell and Gene Therapy. Unveiling the Impact of Global Regulations, Analyzing Success Stories, Empowering Enterprises to Build Efficient and Compliant Systems, and Safeguarding the Delivery of Innovative Therapies to Patients Worldwide.

Send Offers

Xingcheng BioandLePure BiotechCo-developedGMP-Compliant HEK293 Cell Bank：

·What you see is what you get: certified, fully traceable cell banks are ready to use off the shelf, eliminating the need to purchase separate licenses or establish your own bank.

·Milestone-based installment payments to help alleviate your financial pressure;

·Full GMP-compliant management and production, with guaranteed quality.

Lechun Biotechnology will be giving away items on-site.5 Coupons Worth RMB 30,000Coupon, first come, first served!

Event Agenda

■ 13:30-13:40

Event Expectations and Ecosystem Synergy Support

Xiao Liu | Vice President of Business and Marketing, Xingcheng Biotech

Deputy Director of the MAH Special Committee, China Pharmaceutical Enterprise Management Association

Address and Future Outlook for the Industrial Park

Park Leadership

■ 13:40-14:00 Keynote Speech 1

CMC Pitfall Avoidance Guide for Gene and Cell Therapy

Wang Lijun | CEO of Xingcheng Biotech

■ 14:00-14:20 Keynote Speech 2

Application of Yeasen's Novel PEI Transfection Reagent in Large-Scale AAV Production

Yang Juan | Product Director, Pharmaceutical Line, Yeasen Biotechnology

■ 14:20-14:40 Keynote Speech 3

Applications and Solutions of RNA in Cell Therapy

Wu Xin | Founder & Co-founder of Levostar BioCEO

■ 14:40-15:00 Keynote Speech 4

Application of New Technologies in Gene and Cell Therapy Research and Development

Xu Lingli | Senior Marketing Technical Scientist, Danaher Life Sciences

■ 15:00-16:00 Panel1

How to Help CGT Projects Achieve Key Milestones from Preclinical Stage: Steadily, Quickly, and Cost-Effectively?

· Discussion on Quality Control Strategies and Specific Service Cases

· Party A states its requirements, and Party B proposes solutions

· In Extraordinary Times: How to Foster Positive Engagement with Clients and Join Forces for Mutual Support

Liu Xiao | Xingcheng Biotech, Business DevelopmentDeputy Market DirectorPresident (Host)

Wang Lijun | CEO of Xingcheng Bio

Yuan Jun | Vice President & CTO, Kangsheng Biotech

Huang Rui | Executive President, GenScript Biotech

Wu Xin | Founder of Levostar Biology &CEO

Yin Shigang | Chairman, Sichuan Zhisaiyuanji

■ 16:00-16:20 Tea Break

■ 16:20-16:40 Dialogue

Is CGT Still at the Forefront?

Zou Xi | Investment Director, Legend Capital (Moderator)

Li Kechun | Partner, Yuansheng Venture Capital

Guo Yujie | COO, Unisyn Biotech

■ 16:40-17:40 Panel2

# How Can CGT Companies Effectively Pursue “Financing and Business Development” in the New Landscape?

·Anecdotes from BD Partnership Negotiations

· How to Balance Fundraising and Business Development

· Use “preparedness” to respect uncertainty

Zou Xi | Investment Director, Legend Capital (Moderator)

Wu Chao | General Manager, VCBeat New Medicine (Moderator)

Song Xu | Founder, Lingtaike Bio

Zhang Zhixin | Chairman, Yi An Bo Biotech

Chen Lijing | Jinweike ShengDeputy General ManagerLi

Jiang Zhenggang | Partner/VP/Head of Strategy Center, E-MuFeng Bio

Guo Yujie | COO, Useenobio

Han Yuechen | Head of AstraZeneca Chengdu iCampus

Li Kechun | Partner, Yuansheng Venture Capital

Ling Yan | Deloitte, Managing Partner of the West China Region for IPO Services

■ 18:00-20:30 Dinner Gathering (Invitation Only)

Guest Introduction

Liu Xiao

Xingcheng BioVice President of Business and Marketing

Deputy Director of the MAH Special Committee, China Pharmaceutical Enterprise Management Association

Liu Xiao,Former Head of Marketing, Greater China, Danaher Biotechnology Group; previously held positions including Asia-Pacific Marketing Director, Greater China Marketing Director, Consumables Sales Manager, Business Development Manager, and Product Manager at companies such as Cytiva, GE Life Sciences, PerkinElmer, and Thermo Fisher Scientific.

Ph.D. in Strategy, University of Montpellier, France; EMBA, Nankai University; M.Sc. in Biology, University of Manchester; Postgraduate studies in Finance, University of Hong Kong; currently pursuing an M.Sc. in Psychology at Arizona State University, USA. Industry Professor at UCMT; Honorary Director of GDA. Senior Engineer in Measurement, Testing, and Instrumentation (China). Thesis supervisor for Ph.D. in Health Management, DBA, and MBA programs at the University of Montpellier, France.Guest Lecturer, Business School Workshop, The University of Hong Kong; Guest Lecturer, Business School Workshop, Nankai University; Lecturer, Advanced Leadership Training Program in Biopharmaceuticals, Peking University Health Science Center; Guest Lecturer, Yihong Business School. Vice Chairman, Marketing Authorization Holder (MAH) Special Committee, China Pharmaceutical Enterprise Management Association; Chief Researcher, Life Sciences Enterprise Research Center, E-Drug Manager; Special Researcher, China Biomedical Infrastructure Alliance. Planner/Host, “ChatCGT” Column.

Wang Lijun

CEO of Xingcheng Bio

Lijun Wang has over 20 years of comprehensive experience in the biopharmaceutical industry, with nearly 17 years dedicated to gene therapy, viral vector process development, and cGMP manufacturing. As an innovative leader in AAV process development, he specializes in large-scale cell culture, viral vector purification, and analytical methods. He possesses extensive GMP manufacturing experience with AAV, lentivirus, adenovirus, and oncolytic herpes simplex virus, is well-versed in CMC regulations, participated in the design of multiple cGMP production facilities, led and successfully delivered multiple clinical batches of viral vectors, and has rich team management experience. His previous employers include AGTC, Brammer Bio, and Encoded Therapeutics.

Yang Juan

Yisheng Biotech, Pharmaceutical Line Product Director

Yang Juan, a graduate of Zhejiang University, currently serves as the Pharmaceutical Product Line Director at Yeasen Biotechnology (Shanghai) Co., Ltd. She specializes in product design and marketing within the biopharmaceutical sector, with management responsibilities encompassing new product development, product lifecycle management, industry-specific application solutions, and market expansion. Under her leadership, the team has long served clients in key biopharmaceutical fields such as cell and gene therapy, mRNA medicine, vaccines, and antibody drugs, delivering numerous successful collaborative projects.

Wu Xin

LevoStar Bio Founder & CEO

Dr. Wu Xin earned her bachelor’s degree from the Department of Biological Sciences at Tsinghua University and obtained her Ph.D. in Biophysics from Cornell University in the United States in 2009. She previously served as General Manager of Suzhou Genewiz Biotechnology Co., Ltd., accumulating extensive experience in the operation and management of contract research organizations (CROs). In early 2022, Dr. Wu founded Levostar Biosciences, a company dedicated to the development of foundational technologies for innovative therapies and the safety testing and release of biological products. Leveraging profound expertise and leading technical capabilities in the stable production of RNA plasmids, innovative solutions for supercoiled monomers, and process development, Levostar Biosciences has established robust partnerships with numerous renowned industry players, jointly accelerating the development and application of innovative therapies.

Xu Lingli

Danaher Life Sciences, Senior Market Technology Scientist

Xu Lingli joined Danaher in 2012 and has previously worked at Beckman Coulter and SCIEX, where she was engaged in application development, technical support, and marketing related to genetic analyzers and capillary electrophoresis systems. She possesses extensive experience in molecular diagnostics as well as the characterization and quality control of biopharmaceuticals. Currently, she is responsible for the integration and promotion of comprehensive solutions in the pharmaceutical sector within the Strategic Marketing Department of Danaher’s Life Sciences Platform.

Yuan Jun

Kangsheng Biotech Vice President & CTO

Yuan Jun serves as Vice President of Zhongshan Kangtian Shenghe Biotechnology Co., Ltd. He graduated from École Centrale de Lyon and has 14 years of experience in the biopharmaceutical industry. He has participated in and led the design and development of innovative protein therapeutics, overseeing more than 10 pilot-scale R&D projects, successfully filing seven IND applications, and advancing two industrialization projects.

Huang Rui

GeneChem, Executive President

Huang Rui, Executive President of VectorBuilder, holds a Master of Laws from Sun Yat-sen University and is currently pursuing a Master’s degree in Biology at Jinan University. With prior experience at the Guangdong Provincial Government and Liandong Group, he brings over ten years of expertise in business management and project investment. He is currently responsible for strategic affairs, external relations, brand marketing, and comprehensive administrative operations at VectorBuilder.

Zou Xi

Legend Capital, Investment Director

Zou Xi holds a Bachelor’s degree from the College of Life Sciences at Beijing Normal University and an MBA in International Business Administration from the School of Economics and Management at Tsinghua University. He joined Legend Capital in 2018 and currently serves as Investment Director of its Healthcare Fund. With six years of experience in the biopharmaceutical industry and six years in healthcare investment, he previously held the positions of Vice President of Investment at CSC Financial Capital and Strategic Manager in the Strategy and Business Development Department at Pfizer China.

Representative investment projects include GenScript ProBio, Hanbang Technology, Pharmaron (Kunling Pharma), DiMai Biologics, Docreate Pharmaceutical, Promab Biosciences, and Gebo Biologics. Key sectors of focus include upstream pharmaceutical service/equipment/consumables suppliers, antibody-based therapeutics and their derivatives (bispecific antibodies, ADCs, etc.), radiopharmaceuticals, protein degradation, and synthetic biology.

Xu Song

Founder of Lingtaike Bio

Song Xu is a Professor and Doctoral Supervisor at Sichuan University, Chief Scientist of the National Key Research and Development Program, Executive Director of the Chinese Society of Genetics, and Chairman of the Sichuan Society of Genetics. As one of the pioneers in the field of long non-coding RNA (lncRNA), he has been dedicated to investigating lncRNA-protein interactions and their significance in tumorigenesis and tumor progression. Notably, a series of papers published between 2002 and 2009 elucidated the specific mechanisms and effector patterns by which lncRNAs participate in cancer development, representing foundational work in the field of lncRNA-protein interactions. Building on his extensive expertise in lncRNA research, he has recently developed a suite of platform technologies for the druggability of lncRNAs.

Zhang Zhixin

Yi An Bo Bio, Chairman

Professor Zhang has long been engaged in research on B cell development, the molecular regulation of antibody gene recombination, and autoantibodies, antiviral antibodies, and anti-tumor antibodies. For over a decade, he has led and completed more than ten research projects funded by the U.S. National Institutes of Health (NIH) and private foundations (DANA Foundation, LRI). He serves as Vice Chairman of the Scientific Committee on Biological Therapy in China and Director of the Professional Group on Antibodies and Immune Profiling; Vice Chairman of the Scientific Committee on Precision Medicine in China; and Tenured Professor at the University of Nebraska Medical Center. He previously conducted postdoctoral research on B lymphocyte development under the mentorship of renowned immunologist Max D. Cooper. Professor Zhang has published more than 40 articles in academic journals such as Nature Immunology, Immunity, Blood, Immunological Reviews, Trends in Immunology, Journal of Clinical Investigation, and Proceedings of the National Academy of Sciences. He has served as a reviewer for NIH and NSF research grants and for the Lupus Research Institute in the United States, as well as for key projects of the National Natural Science Foundation of China, the NSFC Grand Award, and the Changjiang Scholars Program. He has undertaken multiple key projects supported by the Ministry of Science and Technology and the National Natural Science Foundation. In 2016, he founded Chengdu YiAnBo Biotechnology Co., Ltd.

Chen Lijing

Jinweike Biotechnology, Deputy General Manager

Li Jingchen, Deputy General Manager of Chengdu Jinweike Biotechnology Co., Ltd., has many years of experience in capital operations within the biopharmaceutical industry. He has led multiple equity financing and investment projects valued at over 100 million yuan and is currently responsible for Jinweike’s investment and financing activities as well as its strategic development.

Jiang Zhenggang

Yimufeng Biotech, Deputy General Manager

Jiang Zhenggang, Ph.D. in Immunology, MBA. He earned his bachelor’s and doctoral degrees from Shanghai Medical College of Fudan University and his Master of Business Administration from Fudan University. With over 10 years of experience as a senior executive at domestic innovative pharmaceutical companies, he possesses comprehensive expertise in the operation of biopharmaceutical enterprises, including R&D management, corporate operations, business collaboration, and strategic planning. He previously held senior executive positions at Zesheng Technology and Ascletis Pharma. Currently, he serves as Partner, Deputy General Manager, and Head of the Strategy Center at Emtune Biotechnology Co., Ltd.

Guo Yujie

COO, UcellBio

Dr. Yujie Guo holds a Ph.D. in Biomedical Sciences from Oklahoma State University, USA. Prior to co-founding Useno Biosciences, Dr. Guo served as Vice President at Sequoia Capital China and General Manager of the Pharmaceutical Investment Department at Yuexiu Industrial Fund. He participated in investments in more than 50 biopharmaceutical startups and co-founded Guangzhou Hanteng Biotechnology and Respiron Biotechnologies, Inc. in the United States. Previously, Dr. Guo was involved in clinical trial management at Altheus Biotechnologies, Inc. in the US and worked at the Technology Licensing Office of Oklahoma State University.

Li Kechun

Partner, Origin Capital

Ken Li, Partner at Yansheng Venture Capital; possesses extensive experience in pharmaceutical R&D, entrepreneurship, and investment in both China and the United States; spent over 20 years at Pfizer (New York) and Eisai (Boston) engaged in new drug R&D, pilot-scale testing, manufacturing, and management; participated in the R&D and commercialization of Eribulin, an anti-cancer novel drug whose synthesis involves 62 steps, known as the "Mount Everest" of chemical pharmaceuticals; formerly served as General Manager of Chiral Quest Inc. (a U.S.-listed company) in China, and co-founded Kairuide, a leading enterprise in chiral drugs; led or participated in investments in more than 30 companies, including United Imaging Healthcare (688371), Ascentage Pharma (06855), JW Therapeutics (02126), Anluo Pharmaceutical (ANL), Changfeng Pharmaceutical, Meisai Biologics, Faber New Tian, Jinlan Gene, Real Dimension, Chuangmo Biologics, Sironax, Youjiali, and Sumai Medical; serves as an Editorial Board Member of Progress in Pharmaceutical Sciences, Advisor to the Sino-America Pharmaceutical Association (SAPA), and Founder of SAPA-NE (New England, Boston area), the first chapter of SAPA; holds a Bachelor’s degree in Pharmacy from West China University of Medical Sciences, a Master’s degree in Chemistry from the City College of New York, and an MBA from Babson College.

Wu Chao

General Manager, Arterial Network New Medicine

Wu Chao earned his bachelor’s and master’s degrees from the School of International Pharmaceutical Business at China Pharmaceutical University. With over a decade of experience in the pharmaceutical industry, he has extensive expertise in industrial research and project collaboration. He previously held positions at the Strategy Department of China Resources Sanjiu, the China Resources Group’s Xiong’an New Area Working Group, and Xi’an Jiaotong-Liverpool University, where he engaged in strategic research, industry-city development planning, commercialization of scientific achievements, and innovation ecosystem building. In 2021, he joined VCBeat and co-founded the VB New Medicine media and research platform. He has established in-depth content coverage and resource accumulation in frontier therapeutic areas and indications such as radiopharmaceuticals, organoids and organ-on-a-chip, cell and gene therapy (CGT), and non-alcoholic steatohepatitis (NASH), fostering new consensus and connections within the industry.

*The above guests are listed in agenda order, not in any particular sequence.

*Swipe to view more details

Company Profile

About Xingcheng Biotech

CoJourney is a professional gene and cell therapy CDMO integrating plasmid, viral vector, and mRNA production, preparation, and analytical testing. It has successful experience in submitting Investigational New Drug (IND) applications for plasmids and viral vectors in both China and the United States, achieving zero deficiency letters. The company provides customized services including process development, cGMP manufacturing, analytical method development, and product release testing for plasmids, viral vectors, and mRNA.

Xingcheng Biopharma was co-founded by senior CMC experts with commercialization experience in the gene and cell therapy sector, alongside accomplished scientists and entrepreneurs. With dual headquarters located in Zhejiang, China, and Pennsylvania, USA, the company has established GMP manufacturing facilities for plasmids, viral vectors, and mRNA that comply with FDA, EU, and NMPA regulations. Equipped with advanced production and analytical instrumentation, our team possesses extensive process development capabilities and practical expertise. Upholding the philosophy of “Action Rooted in Sincerity,” we leverage robust processes that exceed industry standards to provide partners with high-purity, high-yield, and cost-effective services for the preparation of plasmids, viral vectors, and mRNA at various production scales, from R&D to GMP grade.

About Yeasen Biotechnology

Yeasen Biotechnology (Shanghai) Co., Ltd. is a high-tech enterprise focused on core raw materials in the upstream life science industry chain, engaged in the research and development, production, and sales of biological reagents across three major categories: molecular, protein, and cellular. By integrating technological development pathways for molecular enzymes, proteins, antibodies, nucleic acids, and cells, Yeasen Biotechnology has become one of the few companies in China that simultaneously covers all three major categories of biological reagents, possessing both independent R&D capabilities for core technologies and large-scale production capacity.

The company develops, manufactures, and sells thousands of types of biological reagents, meeting customers’ integrated procurement needs for various categories of biological reagents. Its core product portfolio spans multiple categories, including qPCR series, NGS series, reverse transcription series, nucleic acid extraction and purification series, PCR series, molecular cloning series, in vitro transcription series, antibodies, protein purification series, protein analysis series, recombinant proteins, cell analysis series, cell culture series, cell transfection series, and reporter gene detection series. These products are widely applied in fields such as life science research, diagnostic testing, and biopharmaceuticals.。

About Lechun Biologics

Shanghai Lepu Biotechnology Co., Ltd., established in 2011, has incorporated leading brands such as Grise Fluid, Kangsheng Biology, and Stanleys through an inorganic growth strategy. Its business now spans multiple application scenarios, including cell culture, filtration and purification, single-use systems, and industrial-grade contamination-free clean solutions. The company has become a widely recognized top-tier supplier offering end-to-end upstream biopharmaceutical process solutions.

Mission & Vision: Driven by technological innovation, we provide high-quality bioprocessing solutions and are committed to becoming the most trusted partner for global biopharmaceutical companies.

About GeneCreate

VectorBuilder (Guangzhou) Biotechnology Co., Ltd., founded in 2014 by the world-renowned molecular biologist Dr. Tian Lan, is a leading enterprise in gene delivery. The company provides comprehensive services across the entire gene delivery industry chain, including research vector construction, gene delivery CRO, and gene vector CDMO. With more than 10 subsidiaries and offices worldwide, VectorBuilder was recognized as a global unicorn in 2023. Its proprietary "VectorBuilder" platform has pioneered the era of commercialized custom gene vectors, serving over 4,000 research institutions and pharmaceutical companies in more than 90 countries and regions. Research outcomes facilitated by its services have been widely cited in thousands of articles published in top-tier scientific journals such as Science, Nature, and Cell. Since entering the clinical market, its gene therapy CRO and CDMO projects have expanded to cover multiple countries and regions, including North America, Europe, and Japan.

Yunzhou Biotech provides end-to-end services from research to clinical applications:

1. Research Vectors and Viral Services

Vector construction, viral packaging, etc.

2. CRO Services

Directed evolution of AAV capsids, library construction, mRNA gene delivery solutions, and generation of stable cell lines.

3. CDMO Services

Process development, analytical method development, plasmid preparation, viral vector preparation, IVT mRNA and LNP preparation, cell bank establishment, etc.

GeneCodis is committed to systematically overcoming key technical bottlenecks in the gene delivery industry, empowering basic scientific research, accelerating the clinical application of gene therapies, improving human health, and creating irreplaceable value for the world.

About Danaher Life Sciences

At Danaher, we converge science, technology, and operational expertise to accelerate the impact of future technologies on today’s lives. Partnering with customers worldwide, we craft solutions to address their most complex challenges, turning the power of science into reality. Our global team is shaping the future of life sciences, medical diagnostics, biotechnology, and more. The Danaher Life Sciences platform serves leading life sciences companies globally, accelerating breakthrough innovations to enable healthier lives for humanity. We maintain long-term collaborations with scientists in research, clinical, and government institutions, leveraging our strengths in science and operations to help them deepen their understanding of disease principles and mechanisms, develop more effective therapies, and create more efficient workflows. Together, we accelerate the positive impact of life sciences on human life.

Danaher China Life Sciences Platform was established on June 1, 2019, with the aim of rooting itself in the Chinese market to provide superior products and services to users in China, focusing on creating comprehensive integrated solutions for precision medicine and biopharmaceuticals. The platform currently boasts numerous well-known brands, including IDT, Beckman Coulter Life Sciences, Molecular Devices, SCIEX, Agela-Phenomenex, Leica Microsystems, Aldevron, and Pall. In the fields of precision medicine and biologics, Danaher Life Sciences continuously develops and refines relevant analytical solutions and workflows based on the actual application scenarios of its Chinese customers. It currently offers multidimensional and rich solutions in areas such as synthetic biology, multi-omics research, organoid research, precise tumor diagnosis and treatment, infectious disease testing, and maternal and child health testing. Furthermore, it provides comprehensive, mature, and highly competitive end-to-end solutions—from R&D to quality control analysis—for a wide range of biologics, including antibody drugs, gene therapies, cell therapies, nucleic acid therapeutics, and novel vaccines.

About Levostar Bio

LevoStar Biologics is a technology-driven enterprise dedicated to the development of foundational technologies for innovative therapies and their efficient manufacturing, aiming to provide leading-edge technologies and comprehensive solutions for nucleic acid drugs and cell and gene therapy (CGT) products. The company boasts multiple core technology platforms, including traceable plasmid synthesis, plasmid process development and manufacturing, RNA synthesis and delivery, as well as analytical method development and quality research for nucleic acid and CGT products, thereby offering customers end-to-end solutions from sequence design to RNA drug production.

In the development of foundational RNA technologies, Levostar Bio possesses industry-leading capabilities. The company’s monoPlasmid platform leverages cutting-edge patented synthetic biology technologies, centering on the mRNA-specific pLevoD series of plasmids and proprietary engineered bacterial strains. By combining directed evolution with AI-driven screening, the platform has innovatively optimized plasmid control elements and edited specific host strains. This approach effectively suppresses multimer formation while maintaining the stability of the plasmid Poly(A) tail across multiple generations, thereby addressing multiple CMC challenges associated with mRNA plasmids in a single integrated solution.

Guided by the principles of professionalism, integrity, openness, pragmatism, equality, and mutual benefit, Levostar Bio is committed to partnering with biopharmaceutical companies to accelerate medical innovation and support drug development, with the ultimate goal of keeping disease at bay for everyone.

About Legend Capital

Legend Capital was established in April 2001 and is a leading fund management firm in China specializing in early-stage venture capital and growth-stage private equity investments. Over the past two decades, Legend Capital has adhered to international standards, establishing best practices in fund operations and management. Through its proactive value-added service system, Legend Capital fosters innovative growth in portfolio companies, delivering consistent strong investment returns across multiple sectors while driving industrial advancement and social development in China. With the vision of “becoming an investment firm with global influence,” Legend Capital upholds the core value of “Prosperity with Integrity” and actively fulfills its social responsibilities.

Legend Capital has maintained a deep focus on investments in the healthcare and medical sector, systematically building its portfolio across the broader health industry. In this field, several of its portfolio companies—industry leaders in their respective niches, including Pharmaron (300759.SZ) (03759.HK), WuXi AppTec (603259.SH) (02359.HK), WuXi Biologics (02269.HK), Innovent Biologics (01801.HK), New Horizon Health (06606.HK), and Mingde Biology (002932.SZ)—have been listed on both the A-share and Hong Kong stock exchanges.

About Chengdu Tianfu International Bio-town

Chengdu Tianfu International Bio-town is a specialized bio-industry park jointly established by the Chengdu High-Tech Zone and Shuangliu District in 2016, covering an area of approximately 44 square kilometers. Ranked fourth among national biomedical parks by the Ministry of Science and Technology, Chengdu Tianfu International Bio-town aims to become a global hub for innovation and entrepreneurship in pharmaceuticals and healthcare, striving to build a world-class center for biological industry innovation and intelligent manufacturing.

The Bio-City focuses on the “5+18” industrial sectors, implementing targeted investment promotion and precise incubation. Specifically, it targets five sub-sectors and 18 specific tracks to foster a cluster of industrial groups. To date, it has partnered with over 2,600 enterprises, introduced more than 400 projects, and attracted total investments exceeding RMB 120 billion.

BioCity focuses on building specialized industrial parks. Currently, the total floor area of delivered and under-construction facilities exceeds 1 million square meters. It aims to provide integrated innovation platforms that combine “seedling, incubation, R&D, and pilot-scale testing,” offering professional supporting services to biopharmaceutical enterprises.

About VBInsight

VBPharma is a media and research platform under VCBeat that focuses on the biopharmaceutical sector. It provides “in-depth” and “incremental” communication value to innovators and entrepreneurs through two dimensions: content and operations. In terms of content, it primarily features exclusive financing announcements, corporate interviews, the “Drug Developers” column, in-depth industry analyses, and sector reports. On the operations front, its branded program “VB Think Tank” focuses on practical challenges, discusses industrial trends, and fosters tangible collaborations through the exchange of ideas.

Thematic Achievements: [CGT】【IPO-Financial Report Analysis】【iPSC】【Nuclear Medicine】【Protein Degraders】【Upstream Tools】【Synthetic Biology】【Organoids】【VB Think Tank].

Previous Reviews

Nine Organizations Join Forces to Kick Off the CGT Industry Upgrade Park Tour at Its First Stop: “Shanghai ATLATL Innovation Center”!

Ten Organizations Join Forces to Visit the Second Stop of the CGT Industry Upgrade Park Tour: “Shanghai Xingbei · Free Trade Zone No. 1”!

Ten Organizations Join Forces to Visit the Third Stop of the CGT Industry Upgrade Park Tour: "Nanjing Bio-Medicine Valley"!

Eleven Organizations Join Forces to Visit the Fourth Stop of the CGT Industry Upgrade Park Tour: “Suzhou BioBAY”!

Eleven organizations join forces to visit the fifth stop of the CGT Industry Upgrade Park Tour: “Beijing Newborn Nest Innovation Center”!

Eleven organizations join forces to visit the sixth stop of the CGT Industry Upgrade Park Tour: “Beijing Yichuang Gaoke Innovation Technology Park”!

Eleven Organizations Join Forces to Visit the Seventh Stop of the CGT Industry Upgrade Park Tour: “Guangzhou International Business Incubator”!

Fifteen Organizations Join Forces: Checking In at the 8th Stop of the CGT Industry Upgrade Park Tour—Shenzhen Weiguang Life Science Park & Bay Gravity!

BD Heats Up, Innovation Cycle Continues: Where Are Nucleic Acid Therapeutics Headed? (VBEF Station - RNA Forum)

Returning to Clinical Needs, Guided by Commercial Value: How to Seize the Opportunity in the Current CGT Sector? (VBEF Station - CGT Forum)